It appears the answer to your question is 'Yes, you can skip' as...

First 152 Last

Share
Profile

Follow
nashezz

2,744 Posts.

1051

28/05/24

12:55

Post #: 74043645
Share

Originally posted by baldwidx ↑

Eagle - I wonder if you or some other posters might have more insight into the following.

Do you know if you can go straight to a P3 trial for an indication, in a drug that has been proven to be safe and effective? For example, if we get PMS and PHS through registration and into sales, presumably the FDA has deemed the drug to be not just effective v placebo, but safe.

JP referenced this yesterday when he mentioned not needing to undertake P2 trials given they are mainly used to determine dosing and safety. If we take appropriate dosing as a given, following his comments and if we take safety as a given, especially if we took one or both conditions through registration, then is it possible that we have a "straight to P3" pass?

If that is possible, then I think that SIGNIFICANTLY changes the landscape for Neuren - I can't see a TO being accepted unless its absolutely astronomical - numbers we don't even dare to discuss. Why would you not run through P3 after P3 yourself and keep all the profit??

if you have sufficient funds in the short term to run the PMS and PHS trials through to marketing, you may need a small CR (pending updated Daybue Revenue) to keep the lights running but you would quickly bring in so much money from those two that can be reinvested into AMS and then PWS and so on.

It really does shift the paradigm but I guess its all predicated on whether a "straight to P3" scenario is possible.

Has anyone come across it before in a similar platform drug?

Expand

It appears the answer to your question is 'Yes, you can skip' as detailed in attached paper. You can also do combined Ph2/3 trials.

https://www.sciencedirect.com/science/article/abs/pii/S0895435623000793

NEU Price at posting: $23.45 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

MTM

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: IT surges as Miners dumped | June 18, 2025

First 152 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.92		Change 0.070(0.54%)		Mkt cap ! $1.607B

Open	High	Low	Value	Volume
$13.15	$13.37	$12.85	$8.049M	616.1K

Buyers (Bids)

No.	Vol.	Price($)
2	4175	$12.91

Sellers (Offers)

Price($)	Vol.	No.
$13.03	100	1

View Market Depth

No.	Vol.	Price($)
2	4175	12.910
4	4488	12.900
2	1762	12.890
2	3348	12.880
1	1508	12.850

Price($)	Vol.	No.
13.030	100	1
13.040	6060	2
13.050	1508	1
13.060	7205	8
13.080	1508	1

Last trade - 16.10pm 18/06/2025 (20 minute delay)

NEU (ASX) Chart

It appears the answer to your question is 'Yes, you can skip' as...

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: IT surges as Miners dumped | June 18, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

It appears the answer to your question is 'Yes, you can skip' as...

Top Stories

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

Almonty Industries – Now it is getting critical!

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

ASX Market Close: IT surges as Miners dumped | June 18, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News